Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.38 (market cap $29.60B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.68. The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | VTIP | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | — |
52-Week High | $491.22 | $50.75 |
52-Week Low | $205.48 | $49.39 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
VTIP trades at $49.695 with minimal daily movement (+0.03%). Technical indicators show a neutral overall signal with bearish moving averages, while RSI readings suggest balanced momentum. The ETF focuses on short-term inflation-protected securities, offering protection against rising costs with current inflation projections around 3.8%. Recent institutional buying includes 55 North Private Wealth increasing holdings by 12.2%.
VTIP provides inflation hedging with expected returns slightly above comparable treasuries. The Fed's stance against rate cuts in 2026 supports short-term TIPS, though inflation volatility remains a key risk. Analyst sentiment is cautiously positive given the inflation environment, making VTIP a strategic defensive holding for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
